Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial of COVIDTRAP(STI-4398) to Evaluate the Safety and Efficacy of STI-4398 for the Potential Treatment of Infected Patients and as a Potential Prophylactic Treatment to SARS-COV-2 Coronavirus Disease (COVID-19)

Next Previous
Trial Profile

A Clinical Trial of COVIDTRAP(STI-4398) to Evaluate the Safety and Efficacy of STI-4398 for the Potential Treatment of Infected Patients and as a Potential Prophylactic Treatment to SARS-COV-2 Coronavirus Disease (COVID-19)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STI 4398 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2020 New trial record
    • 05 Jun 2020 According to a Sorrento Therapeutics media release, the company looks forward to evaluating the safety and efficacy of STI-4398 in clinical trials and, assuming receipt of all requisite approvals, ultimately manufacturing this potentially life-saving compound as a potent anti-COVID-19 antidote available in the armamentarium of physicians fighting the COVID-19 pandemic.
    • 05 Jun 2020 According to a Sorrento Therapeutics media release, Sorrento has discussed with the Food and Drug Administration the development of STI-4398 and has received guidance on the path forward to a clinical trial for STI-4398 (COVIDTRAP), for both the potential treatment of infected patients and as a potential prophylactic treatment to COVID-19.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top